These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34862115)

  • 1. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.
    Hernández-Camba A; Arranz L; Vera I; Carpio D; Calafat M; Lucendo AJ; Taxonera C; Marín S; Garcia MJ; Marín GS; Rodríguez ES; Carbajo AY; De Castro ML; Iborra M; Martin-Cardona A; Rodríguez-Lago I; Busquets D; Bertoletti F; Ausín MS; Tardillo C; Malaves JH; Bujanda L; Castaño A; Domènech E; Ramos L; ;
    Dig Liver Dis; 2022 May; 54(5):635-641. PubMed ID: 34862115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and review.
    Smith MR; Cooper SC
    J Crohns Colitis; 2014 Aug; 8(8):890-7. PubMed ID: 24507162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of mycophenolate mofetil in inflammatory bowel disease.
    Tan T; Lawrance IC
    World J Gastroenterol; 2009 Apr; 15(13):1594-9. PubMed ID: 19340901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
    Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.
    Fellermann K; Steffen M; Stein J; Raedler A; Hämling J; Ludwig D; Loeschke K; Stange EF
    Aliment Pharmacol Ther; 2000 Feb; 14(2):171-6. PubMed ID: 10651657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil therapy for refractory inflammatory bowel disease.
    Palaniappan S; Ford AC; Greer D; Everett SM; Chalmers DM; Axon AT; Hamlin PJ
    Inflamm Bowel Dis; 2007 Dec; 13(12):1488-92. PubMed ID: 17924566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate].
    Hafraoui S; Dewit O; Marteau P; Cosnes J; Colombel JF; Modigliani R; Cortot A; Lémann M
    Gastroenterol Clin Biol; 2002 Jan; 26(1):17-22. PubMed ID: 11938035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.
    Macaluso FS; Maida M; Renna S; Orlando E; Affronti M; Sapienza C; Dimarco M; Orlando R; Rizzuto G; Cottone M; Orlando A
    Dig Liver Dis; 2017 Feb; 49(2):157-162. PubMed ID: 27876682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.
    Orth T; Peters M; Schlaak JF; Krummenauer F; Wanitschke R; Mayet WJ; Galle PR; Neurath MF
    Am J Gastroenterol; 2000 May; 95(5):1201-7. PubMed ID: 10811328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.
    Rodríguez-Lago I; Castro-Poceiro J; Fernández-Clotet A; Mesonero F; López-Sanromán A; López-García A; Márquez L; Clos-Parals A; Cañete F; Vicuña M; Nantes Ó; Merino O; Matallana V; Gordillo J; Elorza A; Vicente R; Casanova MJ; Ferreiro-Iglesias R; Pérez-Galindo P; Benítez JM; Taxonera C; García MJ; Martín E; Aguirre U; Gisbert JP;
    Aliment Pharmacol Ther; 2020 May; 51(9):870-879. PubMed ID: 32181930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model.
    Lv QK; Liu JX; Li SN; Gao YJ; Lv Y; Xu ZP; Huang BX; Xu SY; Yang DX; Zeng YL; Liu DF; Wang W
    Int J Mol Sci; 2015 Nov; 16(11):26654-66. PubMed ID: 26561804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF).
    Florin TH; Roberts RK; Watson MR; Radford-Smith GL
    Aust N Z J Med; 1998 Jun; 28(3):344-5. PubMed ID: 9673748
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-dose thioguanine guided by therapeutic drug monitoring is a safe and effective alternative in inflammatory bowel disease patients intolerant to conventional thiopurines.
    Eqbal A; Martin A; Doecke JD; Patrick D
    Intern Med J; 2023 Apr; 53(4):559-567. PubMed ID: 34874611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
    Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
    Torres P; Cañete F; Núñez L; Aguilar A; Mesonero F; Calafat M; Fernández C; Teniente A; Mañosa M; López-Sanromán A; Domènech E
    Dig Dis Sci; 2020 Jul; 65(7):2036-2043. PubMed ID: 31858325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.
    Thomas PWA; den Broeder N; Derikx M; Kievit W; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F
    Inflamm Bowel Dis; 2022 Dec; 28(12):1813-1820. PubMed ID: 35134917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study.
    Simsek M; Schepers F; Kaplan S; van Asseldonk D; van Boeckel P; Boekema P; Dijkstra G; Fidder H; Gisbertz I; Hoentjen F; Jharap B; Kubben F; de Leest M; Meijssen M; Petrak A; van de Poel E; Russel M; van Bodegraven AA; Mulder CJJ; de Boer N
    J Crohns Colitis; 2023 Jun; 17(6):933-942. PubMed ID: 36702552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.